Healthcare
Enliven Therapeutics, Inc.(ELVN)
Live Price
Offline$37.00
+2.46% today
1Y Change
+126.05%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $2.53B
- Revenue Growth
- 0.0%
- EPS Growth
- +3.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Enliven Therapeutics, Inc. (ELVN) is a Healthcare stock with a market cap of $2.53B and listed on NASDAQ. The stock last traded around $37.00 and up 126.0% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +3.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +3.2%, free cash flow +3.8% with operating margin 0.0% and ROIC -26.0%. Stock Foundry combines ELVN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +3.2%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.4% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -1.1% | -3.9% | -7.3% |
2026 Mar 3, 2026 | -14.3% | +4.3% | +5.2% | +36.3% |
2025 Nov 12, 2025 | +25.6% | -0.1% | +8.9% | -7.5% |
Benchmark Edge
ELVN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ELVN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ELVN Max Drawdown
-36.84%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ELVN and SPY.
Company Overview
Enliven Therapeutics, Inc.
NASDAQ Global Select
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
- Leadership
- Richard A. Fair
- IPO Date
- Mar 12, 2020
- Employees
- 62
- Street Address
- 6200 Lookout Road
- Mailing
- Boulder, CO, 80301
- Region
- Boulder, CO, US
- Reporting Currency
- USD
- Investor Line
- 720 647 8519
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 5.1
Growth
- Revenue
- 0.0%
- EPS
- +3.2%
- Free Cash Flow
- +3.8%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -24.2%
- ROIC
- -26.0%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 28.66
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.